Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Summary

This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the signing of informed consent by the subjects to no more than 28 days before the first medication, imaging examinations are allowed to be performed within 28 days before the first medication, and tumor tissue biopsy is allowed to be archived within 6 months before the first medication), a treatment period (including neoadjuvant and surgical treatment), and a follow-up period (including safety follow-up and survival follow-up).

Timeline

Start

2025-06-20

Primary completion

2026-12-01

Completion

2026-12-01

Drugs

Indications